^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chemo- and Targeted Therapy for Patients With HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative
Published date:
07/29/2021
Excerpt:
Patients with triple-negative, programmed cell death ligand-1–positive MBC may be offered the addition of immune checkpoint inhibitor to chemotherapy as first-line therapy.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.21.01374
Source:
Title:
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: A systematic review and meta-analysis
Published date:
12/08/2023
Excerpt:
Results showed an improvement in PFS for patients receiving ICI in addition to chemotherapy (CT) in both the intent-to-treat (ITT) population and PD-L1 positive patients. Increased pCR rates were observed in all patients irrespective of PD-L1 status as well as increased ORR in the ITT which was more notable in PD-L1 positive subjects. While significant improvement in OS was observed only in PD-L1 positive individuals...This study supports the increased efficacy of ICIs in combination with CT compared to CT alone in patients with TNBC, with the most notable benefit observed in PD-L1 positive patients.
DOI:
https://doi.org/10.1002/cam4.6760
Source:
Title:
258P - Immune checkpoint inhibitors addition to chemotherapy in older patients with metastatic triple-negative breast cancer: A systematic review and meta-analysis
Published date:
09/05/2022
Excerpt:
The addition of ICIs to chemotherapy resulted in a better PFS compared with chemotherapy alone (hazard ratio [HR]: 0.70 [0.55-0.89], p= 0.004) in the overall population and in the PD-L1-positive patients (HR: 0.62 [0.46-0.83], p= 0.001)….ICIs + chemotherapy significantly improved PFS in older patients with mTNBC, especially in PD-L1-positive subgroup...
Secondary therapy:
Chemotherapy
